X4 Pharmaceuticals (XFOR) Revenue (2018 - 2026)

X4 Pharmaceuticals (XFOR) has reported Revenue for 5 consecutive years, with $8.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 346.33% year-over-year to $8.8 million; the trailing twelve-month figure through Jun 2026 stood at $15.8 million (down 51.65% YoY), and the FY2025 full-year result was $35.1 million, up 1273.21% from the prior year.
• Revenue advanced to $8.8 million in Q2 2026 per XFOR's latest filing, from $2.7 million in the prior quarter.
• Across five years, Revenue topped out at $28.8 million in Q1 2025 and bottomed at $560000.0 in Q3 2024.
• Historically, Revenue has averaged $5.5 million across 3 years, with a median of $2.0 million in 2025.
• The widest YoY moves for Revenue: up 346.33% in 2026, down 90.6% in 2026.
• Over 3 years, Revenue stood at $1.4 million in 2024, then soared by 79.08% to $2.6 million in 2025, then surged by 242.91% to $8.8 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $8.8 million, $2.7 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.